Cipla’s Avenue Receives Second CRL For Intravenous Tramadol
As Company Continues To Pursue FDA Approval For The Painkiller
Executive Summary
Cipla’s Avenue Therapeutics has received a second complete response letter from the US FDA regarding its new drug application for an intravenous formulation of tramadol. The company has disagreed with the FDA’s observations and said that it will continue to pursue regulatory approval for IV tramadol.
You may also be interested in...
Cipla Builds On Albuterol Share As Investors Await FY23 US Revenue Delta
Cipla signals more US momentum with headroom for albuterol market share expansion, promising prospects for generic Brovana and strong launch line-up in FY23, but analysts also keep close eye on regulatory pre-approval inspection timelines.
Cipla Builds On Albuterol Share, Investors Await FY23 US Revenue Delta
Cipla signals more US momentum with headroom for albuterol market share expansion, promising prospects for generic Brovana and strong launch line-up in FY23, but analysts also keep close eye on regulatory pre-approval inspection timelines.
Kelix Strikes A Deal To Acquire 14 Oncology Injectables
Kelix bio has announced two deals to expand its presence in Africa. The company is set to acquire 14 oncology injectable products from Germany-based Vitane. Furthermore, Kelix has acquired Pharmaceutical Institute, a pharmaceutical company established in Rabat, to enter Morocco. The pan-African company has also invested in Malta.